The Tübingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy

[1]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[2]  L. Karns,et al.  Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. , 2003, International immunology.

[3]  Anne S De Groot,et al.  Bioinformatics tools for identifying class I-restricted epitopes. , 2003, Methods.

[4]  J. Reidhaar-Olson,et al.  The use of bioinformatics for identifying class II-restricted T-cell epitopes. , 2003, Methods.

[5]  T. Waldmann,et al.  Immunotherapy: past, present and future , 2003, Nature Medicine.

[6]  S. Tenzer,et al.  Using the World Wide Web for predicting CTL epitopes. , 2003, Current opinion in immunology.

[7]  Hans-Georg Rammensee,et al.  Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.

[8]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[9]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[10]  Julie McMurry,et al.  Immuno‐informatics: Mining genomes for vaccine components , 2002, Immunology and cell biology.

[11]  D. Jäger,et al.  Clinical cancer vaccine trials. , 2002, Current opinion in immunology.

[12]  Rudolf M. Huber,et al.  Combined transcriptome and genome analysis of single micrometastatic cells , 2002, Nature Biotechnology.

[13]  D. Speiser,et al.  In vivo activation of melanoma‐specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus‐specific T cells , 2002, European journal of immunology.

[14]  B. Leyland-Jones.  Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[15]  T. Wölfel,et al.  The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. , 2002, Journal of immunological methods.

[16]  Peter M. Haverty,et al.  HugeIndex: a database with visualization tools for high-density oligonucleotide array data from normal human tissues , 2002, Nucleic Acids Res..

[17]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[18]  C. Creaser,et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.

[19]  M Vingron,et al.  Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31 , 500-Element cDNA Array , 2001 .

[20]  J. Nesland,et al.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[22]  H. Rammensee,et al.  Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products , 2001, The Journal of experimental medicine.

[23]  D. Speiser,et al.  Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1 , 2001, The Journal of Immunology.

[24]  V. Engelhard,et al.  Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients , 2001, International journal of cancer.

[25]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[26]  K. Hadeler,et al.  PAProC: a prediction algorithm for proteasomal cleavages available on the WWW , 2001, Immunogenetics.

[27]  Donna R. Maglott,et al.  RefSeq and LocusLink: NCBI gene-centered resources , 2001, Nucleic Acids Res..

[28]  J. Dillner,et al.  Immunity to oncogenic human papillomaviruses. , 2001, Advances in cancer research.

[29]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[30]  S. Altschul,et al.  SAGEmap: a public gene expression resource. , 2000, Genome research.

[31]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[32]  D. Jäger,et al.  Clonal expansion of melan a‐specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma‐associated peptides , 2000, International journal of cancer.

[33]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[34]  F. Marincola,et al.  A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 , 2000, The Journal of Immunology.

[35]  D. McNeel,et al.  Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[37]  J. Fay,et al.  Dendritic Cells , 2003, Annals of the New York Academy of Sciences.

[38]  M. Probst-Kepper,et al.  A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.

[39]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[40]  S. Stevanović,et al.  Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules. , 1999, Seminars in immunology.

[41]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[42]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[43]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[44]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[45]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[46]  G. Ogg,et al.  Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood , 1998, Current Biology.

[47]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[48]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[49]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[50]  J. Karbach,et al.  Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens , 1996, International journal of cancer.

[51]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[52]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[53]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Kinzler,et al.  Serial Analysis of Gene Expression , 1995, Science.

[55]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[56]  Mark M. Davis,et al.  T‐Cell Recognition of Antigen , 1995 .

[57]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[58]  J. Schlom,et al.  Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.

[59]  M. Esteban,et al.  Quantification of antigen specific CD8+ T cells using an ELISPOT assay. , 1995, Journal of immunological methods.

[60]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[61]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[63]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[64]  W Wood,et al.  Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.